Corium Announces Issuance of Key U.S. Patent Covering Corplex Donepezil Transdermal System for Alzheimer’s Disease

Corium (NASDAQ:CORI), a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced today that the United States Patent and Trademark Office (PTO) has issued a cornerstone patent related to the company’s Corplex Donepezil Transdermal Delivery System (TDS), a once-weekly patch that delivers the most commonly prescribed medication for Alzheimer’s patients.

As quoted in the press release:

“Our novel Corplex TDS design and formulation technologies were enabling for the once-weekly transdermal delivery of Donepezil,” said Parminder “Bobby” Singh, Ph.D., Chief Technology Officer and Vice President, R&D at Corium, and a co-inventor on the patent.  “The issuance of this patent highlights our innovation in the transdermal delivery of molecules such as donepezil that have previously been very challenging to transport across the skin with traditional patch technologies.”

The new patent is eligible for listing in the U.S. FDA Orange Book, and its life extends at least to July 2037.  It is the first to issue of a series of pending Corium patent applications relating to various aspects of Corplex Donepezil, as well as similar products.

Click here to read the full press release.